European Biotech Is Specialty Pharma
Executive Summary
Europe's investment environment has forced much of the biotech sector to morph into specialty pharma. The situation isn't likely to change fast. Executives had best adapt, rather than complain.
You may also be interested in...
Europe's New Spec Pharma Models
Spec pharma has created significant value in the US, but not, so far, in Europe. Still, Europe's spec pharma hopefuls aren't giving up, and they're trying out variations on the theme--some starting with infrastructure, others with products.
Europe's New Spec Pharma Models
Spec pharma has created significant value in the US, but not, so far, in Europe. Still, Europe's spec pharma hopefuls aren't giving up, and they're trying out variations on the theme--some starting with infrastructure, others with products.
Early Rewards for Careful Targeting in Oncology
Two early-stage cancer deals at the end of last year set a new high for European biotech pre-clinical deal dollars. They also highlighted the growing value, to Big Pharma and Big Biotech, of targeted, well-designed oncology leads, as progress in cancer therapeutics raises the hurdles for new products' potency and selectivity.